Animas Corporation of Chesterbrook recently shared encouraging results from a study working to advance a predictive blood glucose-regulating system for patients with Type 1 diabetes.

Results from this third clinical trial were presented at the 74th Scientific Sessions of the American Diabetes Association in San Francisco, Ca.

Hypoglycemia is one of the main barriers to attaining glycemic control, causing significant morbidity among patients with diabetes.  In the study Animas’ predictive hypoglycemia-minimizing algorithm was capable of maintaining glucose levels above hypoglycemic levels (glucose <70 mg/dL) for an average of 99.1 percent of the time across the 12 study participants. The algorithm parameter investigated in the study, known as the “aggressiveness factor,” affects how readily the algorithm adjusts insulin delivery to prevent or mitigate predicted hypoglycemia.

Significant differences in the system’s insulin dosing response were observed as the aggressiveness factor was varied, which underscores the need for diligence in investigating configurations that will provide the greatest benefit across the patient population.   The FDA has designated closed-loop insulin delivery as one of its “critical path” initiatives.

Aaron Kowalski, vice president of the Juvenile Diabetes Research Foundation, said a predictive algorithm technology that can reduce or potentially avoid hypoglycemic events will results in significant benefit to patients as researchers pursue a broader vision of fully automated artificial pancreas systems.

Animas began collaborating with industry, academia and advocacy organizations, including the JDRF in 2010. Together with these key partners, Animas continues to work toward developing an automated system to help people living with type 1 diabetes better control their disease.

Animas Corporation is part of the Johnson and Johnson family of companies.

______

Top photo credit: aldenchadwick via photopin cc